Company: VRCA
Filing Date: 2025-12-30
Form Type: 8-K
Source: 0001193125-25-335824
Chunk: 1

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-30
Form: 8-K
Item: Item 5.02
Chunk 1
---
, the Compensation Committee considered: (i) the ownership percentage in the Company for Dr. Rieger, Mr. Kirby and the Company’s other officers based on total shares outstanding (inclusive of shares underlying pre-fundedwarrants) is significantly less than amounts owned by such officers at peer companies; (ii) the impact of the loss of any employee, especially members of management, on the Company’s ability to execute its corporate objectives; and (iii) the recent financing activities of the Company and the total shares outstanding, inclusive of shares underlying pre-fundedwarrants.

For Dr. Rieger, the Compensation Committee approved the grant of options to purchase 512,269 shares of common stock with a grant date of December 23, 2025. The options have an exercise price of $8.21, equal to the closing price of the Company’s common stock on December 23, 2025, and are scheduled to vest upon both of the following two conditions being met: (1) the Company’s stockholders approving an amendment to the 2018 Plan to increase the number of shares eligible for issuance pursuant to the 2018 Plan; and (2) (i) 50% of the shares vest on the date that the closing sales price per share of the Company’s Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and (ii) the remaining 50% of the shares vest on the date that the closing sales price per share of the Company’s Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to Dr. Rieger’s continuous service with the Company as of each applicable vesting date. For Mr. Kirby, the Compensation Committee approved the grant of fully vested restricted stock units for 10,000 shares of common stock with a grant date of December 23, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                               Verrica Pharmaceuticals Inc.     
  Date: December 30, 2025      /s/ John J. Kirby                
                               John J. Kirby                    
                               Interim Chief Financial Officer